ACST vs. FBRX, SLGL, QLI, DRRX, ITRM, EYEN, LPCN, VAXX, SPRB, and LEXX
Should you be buying Acasti Pharma stock or one of its competitors? The main competitors of Acasti Pharma include Forte Biosciences (FBRX), Sol-Gel Technologies (SLGL), Qilian International Holding Group (QLI), DURECT (DRRX), Iterum Therapeutics (ITRM), Eyenovia (EYEN), Lipocine (LPCN), Vaxxinity (VAXX), Spruce Biosciences (SPRB), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical preparations" industry.
Forte Biosciences (NASDAQ:FBRX) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are owned by institutional investors. 10.5% of Forte Biosciences shares are owned by insiders. Comparatively, 13.5% of Acasti Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Acasti Pharma had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for Acasti Pharma and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of -0.01 beat Acasti Pharma's score of -0.71 indicating that Acasti Pharma is being referred to more favorably in the news media.
Forte Biosciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.
Forte Biosciences presently has a consensus price target of $2.75, indicating a potential upside of 271.67%. Acasti Pharma has a consensus price target of $6.00, indicating a potential upside of 91.69%. Given Acasti Pharma's higher possible upside, equities research analysts plainly believe Forte Biosciences is more favorable than Acasti Pharma.
Forte Biosciences' return on equity of -13.18% beat Acasti Pharma's return on equity.
Forte Biosciences is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.
Acasti Pharma received 286 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 70.52% of users gave Acasti Pharma an outperform vote while only 56.82% of users gave Forte Biosciences an outperform vote.
Summary
Acasti Pharma beats Forte Biosciences on 10 of the 14 factors compared between the two stocks.
Get Acasti Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acasti Pharma Competitors List
Related Companies and Tools
